PD0325901

Pfizer辉瑞授权 目录号:S1036

PD0325901 Chemical Structure

Molecular Weight(MW): 482.19

PD0325901是一种选择性的,非ATP竞争性MEK抑制剂,无细胞试验中IC50为0.33 nM,对ERK1和ERK2磷酸化抑制作用比CI-1040强500倍左右。Phase 2。

规格 价格 库存 购买数量  
RMB 1149.21 现货
RMB 580.85 现货
RMB 2226.87 现货
RMB 6305.45 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献81篇:

客户使用该产品的19个实验数据:

  • Phosphorylation of PPARg in epididymal white adipose tissue in ob/ob mice after treatment with MEK inhibitors. Gene expression in ob/ob epididymal white adipose tissue after treatment with vehicle or either of two MEK inhibitors, PD0325901 or GSK1120212 (n = 7, 7 and 8, respectively). Areas under the curve and gene expression were analysed by analysis of variance.

    Nature 2015 517(7534), 391-5. PD0325901 purchased from Selleck.

    Immunoblot analysis of Ser9-phosphorylated (that is, inactivated) or total GSK3β, active or total β-catenin Thr202- and Tyr204- phosphorylated or total Erk1/2, and Ser473-phosphorylated or total Akt in control; Bcl2 lymphoma cells treated with ADR for five days, together with pharmacological inhibitors targeting MAPK and PI3K kinase pathways.α -Tubulin was used as a loading control. MAPKi=PD325901.

    Nature, 2018, 553(7686):96-100. PD0325901 purchased from Selleck.

  • c, Examples of CDK2 activity traces aligned to the end of mitosis. Each panel shows different time windows relative to mitosis when mitogens were withdrawn (marked in grey) in d. d, Probability of proliferation (defined as CDK2 activity > 1, 10 h after mitosis) represented as a function of time when inhibitors of MEK (MEKi; 100 nM PD0325901) or of CDK4 (CDK4i; 1 μ M palbociclib) were added or when mitogens were removed, relative to mitosis. Data are mean ± s.e.m. (n = 5 biological replicates).

    Nature, 2017, 549(7672):404-408. PD0325901 purchased from Selleck.

    Immunoblot analysis of Ser9-phosphorylated (that is, inactivated) or total GSK3β , active or total β -catenin (as in Extended Data Fig. 5c), Thr202- and Tyr204-phosphorylated or total Erk1/2, and Ser473-phosphorylated or total Akt in control;Bcl2 lymphoma cells treated with ADR for five days, together with pharmacological inhibitors targeting MAPK and PI3K kinase pathways. α -Tubulin was used as a loading control. One out of two independent experiments shown. MPAKi:PD325901

    Nature, 2017, 553(7686):96-100. PD0325901 purchased from Selleck.

  • Rapamycin reduces VCAM expression in vivo. Expression of VCAM-1 mRNA (normalized to CD31) in aortas harvested from mice pretreated with vehicle, rapamycin, or rapamycin + MEK inhibitor (MEK-I; PD0325901) and then injected with TNF (n = 5 per group). Mice were treated as in D. Harvested aortas were analyzed for VCAM-1 expression via immunofluorescence.

    J Exp Med 2014 211(3), 395-404. PD0325901 purchased from Selleck.

    Plasma MEK inhibitor levels of PD325901 are plotted against % MEK inhibition in brain. One hundred percent pERK levels (0% MEK inhibition) were determined in vehicle-treated rats.Inhibition of pERK activity in brain, lung, and Colo205 tumor in nude xenograft mice treated with 10 mg/kg PD325901.

     

     

    Cancer Res 2009 PD0325901 purchased from Selleck.

  • Pharmacological inhibition of MEK (PD0325901) suppresses DR5 expression in cancer cells; this effect is reversible upon stopping of the treatment. The indicated cancer cell lines were exposed to the given concentrations of the inhibitors as indicated for 16 h. TPC-1 cells were treated with 10 uM of the indicated inhibitors for different times as labeled.

    Oncogene 2015 10.1038/onc.2015.97. PD0325901 purchased from Selleck.

    (B)Effect of MAPK pathway inhibition on FGF9 mediated induction of Fgf23 expression. (D) Western blot analysis of FRS2 and ERK1/2 phosphorylation in UMR 106 cells. Cells were treated for 3h (Western blot) or 24h (qPCR analysis) with FGF9 (50ng/ml), EGF (50ng/ml), PD173074 (250nM), PD0325901 (100nM) and RAF265 (500nM) as indicated. Heparin (10g/ml) was added to all treatments with FGF9. Activation of Fgf23 is shown relative to transcript levels in vehicle treated cells (relative expression of 1). Expression values were normalized to Gapdh mRNA copies and are given as average with SEM (n3). Data were compared by 1 way ANOVA; asterisk indicates p<0.05 with respect to vehicle treated cells.

    J Bone Miner Res 2011 26, 2486-2497. PD0325901 purchased from Selleck.

  • Assessment of in vivo toxicity to MEK inhibitor PD0325901. (A) Weight change in grams is shown for each PD0325901 (PD) treatment group in the MDA-MB-453 xenograft model. Weight change is the difference between pre- and post-treatment weight in each group. PD0325901 treatments were carried out at 5, 10, 15 and 20 mg/kg/day for 30 days, and daily gavage of carrier solution was used as control. *P < 0.01 for PD-5/PD-10 vs. control groups and PD-5/PD-10 vs. PD-15/PD-20 groups using Mann-Whitney U test. Error bars: ±2 SEM. (B) Number of days lost due to toxicity is shown for each PD0325901 treatment group in mouse xenograft model explained in Figure 5A. *P < 0.01 for PD-5/PD-10 vs. PD-15/PD-20 groups.

     

     

    Breast Cancer Res 2011 13, R36. PD0325901 purchased from Selleck.

    The therapeutic effect of AR and MEK inhibitors on in vivo angiogenesis. (A) Angiogenesis index for each in vivo treatment group. Angiogenesis was measured as the number of CD-31-positive blood vessels in a cross-section of each xenograft tumor. CTL: control group; FLU: flutamide; and PD: PD0325901. *P < 0.03 for PD0325901 monotherapy vs. control and **P < 0.03 for combination therapy vs. monotherapy groups using Mann-Whitney U test. Error bars: ±2 SEM. (B) Immunohistochemistry (IHC) was used to measure angiogenesis in a control xenograft tumor. Staining was performed using a CD31 rabbit polyclonal antibody. Original magnification, × 40. (C) IHC was used to measure angiogenesis in a PD0325901 monotherapy tumor. Original magnification, × 40. (D) IHC was used to measure angiogenesis in a xenograft tumor treated with combination therapy. Original magnification, × 40.

    Breast Cancer Res 2011 13, R36. PD0325901 purchased from Selleck.

  • Effects of the MEK inhibitor (MEKi) PD0325901 (PD) and rhBMP-2 (BMP) treatment on histology in an NF1 open fracture model. Treatment with 10 mg/kg of PD0325901 on days 22 through 10 (PD alone) slightly improved bone volume and callus size. Delivery of 10 mg of rhBMP-2 in the collagen sponge (BMP alone) resulted in a large increase in bone volume and callus size. Combination treatment with local rhBMP-2 and systemic PD0325901 (PD 1 BMP) resulted in further increases in new bone volume and total callus volume.Picro Sirius Red and Alcian Blue staining to assess fibrous tissue.

    J Bone Joint Surg Am 2015 96(14), e117. PD0325901 purchased from Selleck.

    Bone 2014 59, 151-61. PD0325901 purchased from Selleck.

  •  

    Characterization of rES cells. A: image of normal rES cell colonies on feeder layers. B: rES colonies were positive for AP staining. CeE: rES colonies readily expressed pluripotent markers, Sox2 (C), Oct4 (D), and SSEA-1 (E). Blue, DAPI. Scale bars: 100 um.

    J Genet Genomics 2012 39, 643e651. PD0325901 purchased from Selleck.

     

    Effect of small molecule inhibitors on reprogramming efficiency of myoblast cell derived from 5 different donors. (A) Reprogramming efficiency is shown as number of colonies from 10^5 starting cells on Y-axes. Ctrl, control condition and addition of small molecule inhibitors are marked. (B) AP staining of reprogrammed myoblast cell lines,from 5 different donors, in wells of 12-well plates at day 18. Ctrl, control condition and additions of small molecule inhibitors are marked.

    Stem Cells Dev 2013 PD0325901 purchased from Selleck.

  • The effects of PD0325901 on the Akt/mTOR and MAPK pathways in the two DDLS cell lines as evaluated by western blotting

    Tumour Biol, 2016, 37(4):4767-76.. PD0325901 purchased from Selleck.

    PD0325901 inhibited the sorafenib-induced RAS/ERK pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (PD0325901, 10 μM). Expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (PD0325901, 10 μM). Expressions of p-AKT and cleaved PARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. Proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. Proportions of apoptotic cells were evaluated by annexin V labeling. (*P<0.05, HUH- 7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. PD0325901 purchased from Selleck.

  • Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. PD0325901 purchased from Selleck.

    Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of  PD0325901 for 24 hours.

     

     

    2010 Dr Zhang of Tianjin Medical University. PD0325901 purchased from Selleck.

  • Effects of PD0325901 on HT29 Xenograft tumors. PD0325901(1mg/kg carrier DMSO).Collection at 24h.

     

     

    2010 Dr. Citrin, Deborah of NIH. PD0325901 purchased from Selleck.

产品安全说明书

MEK抑制剂选择性比较

生物活性

产品描述 PD0325901是一种选择性的,非ATP竞争性MEK抑制剂,无细胞试验中IC50为0.33 nM,对ERK1和ERK2磷酸化抑制作用比CI-1040强500倍左右。Phase 2。
靶点
MEK [1]
(Cell-free assay)
0.33 nM
体外研究

PD0325901比另一种MEK抑制剂CI-1040具有更高的渗透率。与CI-1040相比,PD 0325901可以到达体系的更深层。[1]PD0325901是非ATP竞争性的MAPK激酶MEK抑制剂,抑制鼠类结肠26细胞的MEK时IC50为0.33nM。苏氨酸/酪氨酸激酶MEK是RAS/RAF/MEK/ERK信号通路的关键组成部分,在人类肿瘤细胞中通常是激活的。PD0325901精确有效地抑制MEK,作用于MEK1和MEK2时Ki值为1nM。PD0325901作用于细胞ERK1和ERK2的磷酸化效果比CI-1040强到大约500倍。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human CHP-212 cell Mm\KS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUnJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlUzPyCwTT6= NGnmeItUSU6JRWK=
human M14 cell NUi0TGttT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3TVSGlvcGmkaYTpc44hd2ZiaIXtZY4hVTF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT60OUBvVS5? MoLpV2FPT0WU
human SK-MEL-28 cell MmPrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUXJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2yPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTJibl2u MoLBV2FPT0WU
human NOMO-1 cell NYX6[JU1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYjYOFBzUW6qaXLpeIlwdiCxZjDoeY1idiCQT13PMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB5IH7NMi=> NV\xO2lrW0GQR1XS
human A375 cell M2PMXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmrsTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj62PUBvVS5? NGf3[Y1USU6JRWK=
human DU-4475 cell M3fGN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{\CdmlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvNES3OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPTdibl2u MV3TRW5ITVJ?
human C32 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn7qTY5pcWKrdHnvckBw\iCqdX3hckBEOzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lk[3JI5ONg>? NFrIVXRUSU6JRWK=
human BPH-1 cell NGHQXWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmTqTY5pcWKrdHnvckBw\iCqdX3hckBDWEhvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPVUhdk1w M2LNPHNCVkeHUh?=
human CP50-MEL-B cell M1jpV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1fw[GlvcGmkaYTpc44hd2ZiaIXtZY4hS1B3MD3NSWwuSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwNUigcm0v MnPpV2FPT0WU
human H9 cell NFjxTIlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUfiWo5iUW6qaXLpeIlwdiCxZjDoeY1idiCKOTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|chdk1w MlnjV2FPT0WU
human HTC-C3 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIr3XZlKdmirYnn0bY9vKG:oIHj1cYFvKEiWQz3DN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQDlibl2u MmfMV2FPT0WU
human BHT-101 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mli5TY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44KG6PLh?= MkDzV2FPT0WU
human COLO-741 cell NUPJO|cyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1TGbWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz23OFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjFibl2u M1zCcXNCVkeHUh?=
human OVCAR-5 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX\Xc4x1UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py56MjDuUU4> MWLTRW5ITVJ?
human A549 cell M{DsXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2PZWWlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFkhdk1w NVf4NVFpW0GQR1XS
human SH-4 cell growth NE\IXWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGfk[HJKdmirYnn0bY9vKG:oIHj1cYFvKFOKLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlI3KG6PLh?= MXrTRW5ITVJ?
human SK-N-AS cell MmX2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2XLVGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTj3BV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgvPDRibl2u M{[0ZXNCVkeHUh?=
human HT-144 cell NUDXd2RbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M17qVmlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUS0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE46PyCwTT6= M2\Zc3NCVkeHUh?=
human MEL-HO cell MnvFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVLzcY5PUW6qaXLpeIlwdiCxZjDoeY1idiCPRVytTG8h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjR7IH7NMi=> NHPqc45USU6JRWK=
human COLO-679 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml:0TY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[3PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExNjBzIH7N MVvTRW5ITVJ?
human HuP-T4 cell NFzrZVdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVnJcohq[mm2aX;uJI9nKGi3bXHuJGh2WC2WNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlk5KG6PLh?= NVywRnlNW0GQR1XS
human H-EMC-SS cell NVLUc2x[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmW0TY5pcWKrdHnvckBw\iCqdX3hckBJNUWPQz3TV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjB{IH7NMi=> M4HiXHNCVkeHUh?=
human LB2518-MEL cell M{DITWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG\ZW3ZKdmirYnn0bY9vKG:oIHj1cYFvKEyEMkWxPE1OTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMT6xN{BvVS5? NXTDNGZ7W0GQR1XS
human HL-60 cell M{P5bWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYHPfnhCUW6qaXLpeIlwdiCxZjDoeY1idiCKTD22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjF3IH7NMi=> M13hNnNCVkeHUh?=
human NCI-H1666 cell NIHuN|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXzKXYx5UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PjZiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMT6xO{BvVS5? MmjYV2FPT0WU
human A101D cell NIfsNGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV;TWYJSUW6qaXLpeIlwdiCxZjDoeY1idiCDMUCxSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjR3IH7NMi=> M{mwcnNCVkeHUh?=
human RVH-421 cell MlvPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2n0ZWlvcGmkaYTpc44hd2ZiaIXtZY4hWl[KLUSyNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEzNjZ2IH7NMi=> MnfjV2FPT0WU
human Hs-578-T cell NWTjRWxMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NICyT2tKdmirYnn0bY9vKG:oIHj1cYFvKEi|LUW3PE1VKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTJwN{mgcm0v M{PxfnNCVkeHUh?=
human A375 cells MlvKVJJwdGmoZYLheIlwdiCjc4PhfS=> MnviO|IhcA>? NIPNUY1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO|Uh[2WubIOg[ZhxemW|c3nu[{BDWkGIIG[2NFBGKG23dHHueEBi\nSncjC3NkBpenNiYomgR4VtdCC2aYTldk1odG9iYYPzZZktKEmFNUC9NVMhdk1w M4HLNFI{PDd2M{i4
human DOK cell NI\YS5NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXPJcohq[mm2aX;uJI9nKGi3bXHuJGRQUyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF|LkSgcm0v MnezV2FPT0WU
human Mewo cell MnvYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIfST4FKdmirYnn0bY9vKG:oIHj1cYFvKE2nd3:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE41PSCwTT6= NHrKbFdUSU6JRWK=
human ONS-76 cell NG\r[pRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUK0[mpjUW6qaXLpeIlwdiCxZjDoeY1idiCRTmOtO|Yh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPC53MTDuUU4> NIjDVYpUSU6JRWK=
human UACC-257 cell M{O0eWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlXoTY5pcWKrdHnvckBw\iCqdX3hckBWSUOFLUK1O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjZ{IH7NMi=> MUfTRW5ITVJ?
human SW626 cell NHToOoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml;LTY5pcWKrdHnvckBw\iCqdX3hckBUXzZ{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG0MlkyKG6PLh?= Moe5V2FPT0WU
human SW620 cell MmXxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkizTY5pcWKrdHnvckBw\iCqdX3hckBUXzZ{MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG0Mlk2KG6PLh?= MYPTRW5ITVJ?
human TYK-nu cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1mxemlvcGmkaYTpc44hd2ZiaIXtZY4hXFmNLX71JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvOTNibl2u M3HpeXNCVkeHUh?=
human ACN cell Mnf6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV;3SZRDUW6qaXLpeIlwdiCxZjDoeY1idiCDQ16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU44PiCwTT6= MY\TRW5ITVJ?
human MIAPaCa2 cells MVHQdo9tcW[ncnH0bY9vKGG|c3H5 NVXsV455SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNTWFR[UOjMjDj[YxteyxiSVO1NF0yPyCwTT6= MXqyN|Q4PDN6OB?=
human T-24 cell Mof5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mme5TY5pcWKrdHnvckBw\iCqdX3hckBVNTJ2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUmuO|Ehdk1w NI\EZpJUSU6JRWK=
human AGS cell M3jNZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUPJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJyLkSxJI5ONg>? NVmwVFRqW0GQR1XS
human SW872 cell NFj0eYVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF[4T3JKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlcvQTlibl2u NWrMN3ZiW0GQR1XS
human C2BBe1 cell M3W2Smdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3j2T2lvcGmkaYTpc44hd2ZiaIXtZY4hSzKEQnWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlgvPTRibl2u NUPy[oNDW0GQR1XS
human MZ7-mel cell MlP4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHn1c3NKdmirYnn0bY9vKG:oIHj1cYFvKE2cNz3t[Ywh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zQS52MzDuUU4> MUnTRW5ITVJ?
human HCC2998 cell MnnXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVvoWVI1UW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OyPVk5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzNwNk[gcm0v MkTEV2FPT0WU
human HO-1-N-1 cell MnfGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml\5TY5pcWKrdHnvckBw\iCqdX3hckBJVy1zLV6tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjR|IH7NMi=> MmfxV2FPT0WU
human SW756 cell Mn2yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWLJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{SuOFUhdk1w MYnTRW5ITVJ?
human NCI-H1437 cell Mk[4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn70TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG0N|ch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{PC52OTDuUU4> MmTsV2FPT0WU
human NCI-H747 cell NHPFflRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoH5TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEe0O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1Njl6IH7NMi=> MVnTRW5ITVJ?
human SK-MEL-2 cell NYLSOZBIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|UvOiCwTT6= MXzTRW5ITVJ?
human MZ2-MEL cell Ml:5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWTJcohq[mm2aX;uJI9nKGi3bXHuJG1bOi2PRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOU43PSCwTT6= M37a[HNCVkeHUh?=
human PSN1 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2P4NGlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO4MlQ2KG6P NWXtUlNGW0GQR1XS
human CAL-39 cell NEn6SIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NITk[m9KdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM6NjB2IH7NMi=> MX3TRW5ITVJ?
human LOXIMVI cell MmXDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYe3WJNoUW6qaXLpeIlwdiCxZjDoeY1idiCOT2jJUXZKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzlwM{mgcm0v M3;PSnNCVkeHUh?=
human COLO-792 cell M17rVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkPSTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ{NjF3IH7NMi=> M3zuc3NCVkeHUh?=
human CAL-27 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS0MlkyKG6P MonaV2FPT0WU
human AsPC-1 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M33qdGlvcGmkaYTpc44hd2ZiaIXtZY4hSXOSQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFUvOjhibl2u NWTUVotDW0GQR1XS
human NCI-H2291 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVLJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkK5NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ3NjR4IH7NMi=> NEGyXppUSU6JRWK=
human RCM-1 cell NWO1ZWRJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWn1O415UW6qaXLpeIlwdiCxZjDoeY1idiCUQ12tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ3Njh3IH7NMi=> MnLrV2FPT0WU
human NCI-H292 cell M37K[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1TkT2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Py5|OTDuUU4> NULXeVhbW0GQR1XS
human WM-115 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3rZbGlvcGmkaYTpc44hd2ZiaIXtZY4hX01vMUG1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFgvPSCwTT6= MoPkV2FPT0WU
human RT-112 cell M{\DTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkXQTY5pcWKrdHnvckBw\iCqdX3hckBTXC1zMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20PE45PCCwTT6= NF7tcHBUSU6JRWK=
human HT-29 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGLwR3dKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVAvPDlibl2u MXjTRW5ITVJ?
human RKO cell growth MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUfEfJVxUW6qaXLpeIlwdiCxZjDoeY1idiCUS1:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Nk4xOiCwTT6= NXfHWIE6W0GQR1XS
human KY821 cell M2GydGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGqxbHFKdmirYnn0bY9vKG:oIHj1cYFvKEu\OEKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVMvOyCwTT6= MVvTRW5ITVJ?
human LB1047-RCC cell NELIU3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoTOTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PTlwNkWgcm0v MYfTRW5ITVJ?
human SW1116 cell NYP2OZU4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXvaeXdrUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GxNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03OC52OTDuUU4> NHz0d5RUSU6JRWK=
human P12-ICHIKAWA cell NVvOVpZbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkHVTY5pcWKrdHnvckBw\iCqdX3hckBROTJvSVPITWtCX0FiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14Mj6yO{BvVS5? NF[wOFRUSU6JRWK=
human HCC70 cell M{DuV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVnJcohq[mm2aX;uJI9nKGi3bXHuJGhESzdyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NkOuNFEhdk1w NFjHOpJUSU6JRWK=
human MIA-PaCa-2 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2LLS2lvcGmkaYTpc44hd2ZiaIXtZY4hVUmDLWDhR4EuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ|LkWzJI5ONg>? NEf3OHdUSU6JRWK=
human LoVo cell M3XY[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVTqfFFRUW6qaXLpeIlwdiCxZjDoeY1idiCOb2\vJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OlUvOjlibl2u M1LZdHNCVkeHUh?=
human LB2241-RCC cell MmnUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXHJcohq[mm2aX;uJI9nKGi3bXHuJGxDOjJ2MT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03PS53MjDuUU4> NFS2WY9USU6JRWK=
human GAK cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFPKVHhKdmirYnn0bY9vKG:oIHj1cYFvKEeDSzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[2Mlg4KG6PLh?= NVH4[oIyW0GQR1XS
human RD cell MnvPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWrzcoNxUW6qaXLpeIlwdiCxZjDoeY1idiCURDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[3MlEhdk1w NHHOfo5USU6JRWK=
human KNS-62 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGnmU3lKdmirYnn0bY9vKG:oIHj1cYFvKEuQUz22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVY6Njl7IH7NMi=> MmHWV2FPT0WU
human HD-MY-Z cell NHnOeXRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn\2TY5pcWKrdHnvckBw\iCqdX3hckBJTC2PWT3aJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|EvOTJibl2u MWHTRW5ITVJ?
human COR-L105 cell NGH2RZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWLJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|EvPzFibl2u MlTqV2FPT0WU
human IA-LM cell MluyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGDJOm9KdmirYnn0bY9vKG:oIHj1cYFvKEmDLVzNJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|MvOjhibl2u M1TxcnNCVkeHUh?=
human EM-2 cell MkOzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIG1dpZKdmirYnn0bY9vKG:oIHj1cYFvKEWPLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23OE44KG6PLh?= NHW2R3ZUSU6JRWK=
human NB69 cell M4\p[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkHVTY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYm= M1OxTnNCVkeHUh?=
human HuP-T3 cell MlvvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoToTY5pcWKrdHnvckBw\iCqdX3hckBJfVBvVEOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24N{46OyCwTT6= MWPTRW5ITVJ?
human BB30-HNC cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWLMN41RUW6qaXLpeIlwdiCxZjDoeY1idiCEQkOwMWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTh3LkWxJI5ONg>? MnzRV2FPT0WU
human HT-1080 cell NEjPW2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnOyTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zMEiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFUvQDhibl2u M1W1SXNCVkeHUh?=
human RMG-I cell NVHxfFFNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGfXU5VKdmirYnn0bY9vKG:oIHj1cYFvKFKPRz3JJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFcvOzRibl2u MWrTRW5ITVJ?
human HCC1419 cell NUXuXJliT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYXJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF2MUmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25NU4{QCCwTT6= Mn;MV2FPT0WU
human SW780 cell NIDncGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3m0OmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25Nk4{OiCwTT6= MmLMV2FPT0WU
human SNU-387 cell NHLSWnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVrJcohq[mm2aX;uJI9nKGi3bXHuJHNPXS1|OEegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25N{4{PiCwTR?= NGnCT3FUSU6JRWK=
human LAMA-84 cell M{KycWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3PBdmlvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk1NjZ6IH7NMi=> MkHjV2FPT0WU
human MV-4-11 cell NIT0XXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1HtdmlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk1Njd|IH7NMi=> MoLYV2FPT0WU
human EGI-1 cell M1\jZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGXoZYpKdmirYnn0bY9vKG:oIHj1cYFvKEWJST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PVUvQDFibl2u M4\1fXNCVkeHUh?=
human NCI-SNU-1 cell NXLYcZVpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3\QXGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QTZwN{Ogcm0v MX3TRW5ITVJ?
human MEG-01 cell NIDUVZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFn5W|hKdmirYnn0bY9vKG:oIHj1cYFvKE2HRz2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk4Njd5IH7NMi=> MWPTRW5ITVJ?
human OMC-1 cell M{XmW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlnpTY5pcWKrdHnvckBw\iCqdX3hckBQVUNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwNE4zOyCwTT6= NWP1OWNvW0GQR1XS
human NB10 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUHJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMECuOFIhdk1w NYDObIN7W0GQR1XS
human CAL-62 cell M4fm[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnvnTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFAvPzhibl2u M37S[3NCVkeHUh?=
human NCI-H2087 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1\KZmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFg4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTBzLkG0JI5ONg>? NIHMbZJUSU6JRWK=
human MDA-MB-175-VII cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NW\Rb|VNUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOTd3LW\JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6 NUfWbWUzW0GQR1XS
human LS-513 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWTJcohq[mm2aX;uJI9nKGi3bXHuJGxUNTVzMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxOE45OyCwTT6= Mmn6V2FPT0WU
human HN cell growth MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4D3PWlvcGmkaYTpc44hd2ZiaIXtZY4hUE5iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMkKuOVkhdk1w M2LQbHNCVkeHUh?=
human ABC-1 cell MkXJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1TmNmlvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNlMvODJibl2u MmXnV2FPT0WU
human SJSA-1 cell NIP4cmhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkLWTY5pcWKrdHnvckBw\iCqdX3hckBUUlODLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNlMvOTlibl2u MlnMV2FPT0WU
human PANC1 cells Mk\0SpVv[3Srb36gZZN{[Xl? NXrDVXA4OTBizszN NU\xZ5N4OSCq NIH0cmlKdmirYnn0bY9vKG:oIF3FT|EhcW5iaIXtZY4hWEGQQ{GgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKHCHcnuxM|IhdGW4ZXygZZQhOTBidV2gZYZ1\XJiMTDodkBjgSCZZYP0[ZJvKGKub4T0bY5oKGGwYXz5d4l{ M1m4[FI2PzZ4NkOz
human MCF7 cells NYO5SZlCTnWwY4Tpc44h[XO|YYm= MlXhO|UhdWmwcx?= M4\lSmlvcGmkaYTpc44hd2ZiTVXrNU8zKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hTVKNIIDoc5NxcG:{eXzheIlwdiCjZoTldkA4PSCvaX7zJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM> MVuyN|M6QDR3Mx?=

... Click to View More Cell Line Experimental Data

体内研究 PD0325901阻止细胞黑色素瘤细胞系的生长,使异种移植鼠模型的细胞周期停止在G1期,引起细胞凋亡单独口服25 mg/kg PD032590124后,ERK的磷酸化作用被阻断达到50%以上。PD 0325901的抗癌活性已经被用于更广泛的人类移植瘤的研究中,在研究的人类肿瘤模型中,有6/7被PD 0325901明显抑制。[2] PD0325901抑制恶性黑色素瘤细胞系生长。PD0325901抑制TPC-1细胞和K2细胞生长,GI50分别为11和6.3 nM。PD0325901浓度非常低时(10 nM)也明显抑制携带BRAF突变的PTC细胞生长,且同样浓度时只稍微提高携带RET/PTC1重排的PTC细胞生长。PD0325901作用于多种PTC细胞系,有效抑制ERK1/2磷酸化。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

体外级联实验:

在有含p44MAPK(GST-MAPK)的谷胱甘肽S-转移酶融合蛋白和含p45MEK(GST-MEK)的谷胱甘肽S-转移酶融合蛋白存在情况下,测定32P渗透到髓鞘碱性蛋白(MBP)的渗透率。实验溶液包括20 mM HEPES,pH 为7.4,10 mM MgCl2,1 mM MnCl2,1 mM EGTA,50 mM [gamma-32P]ATP,10 mg GST-MEK,0.5 mg GST-MAPK,和40 mg MBP,终体积为100 mL。实验进行20分钟后,加入三氯乙酸终止反应,然后通过GF/C过滤器过滤。使用1205 Beta板测定保留在过滤器中的32P。测定不同剂量PD0325901,绘制剂量反应曲线。
细胞实验:

[3]

+ 展开
  • Cell lines: PTC细胞
  • Concentrations: 0.1 nM- 1 μM
  • Incubation Time: 48小时
  • Method:

    1×104个PTC细胞接种在含1mL培养基的24孔板上,在37oC下温育4天。在实验第一天加入不同浓度MEK抑制剂,重复三次。MTT溶于0.8% NaCl溶液,浓度为5 mg/mL,实验第三天,每孔加入0.2 mL,测定GI50或者测定每天的细胞生长曲线。细胞和MTT在37oC下温育3小时。然后从孔中吸出液体除去。染色的细胞溶于0.5 mL DMSO,然后使用Synergy HT增殖酶标仪在570 nm处测定吸光值。然后测定GI50, 按公式 100×(T − T0)/(C − T0)计算细胞生长。


    (Only for Reference)
动物实验:

[3]

+ 展开
  • Animal Models: 携带PTC细胞的Ncr-nu/nu鼠
  • Formulation: 80 mM柠檬酸缓冲液(pH 7)
  • Dosages: 20-25 mg/kg
  • Administration: 口服饲喂
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 96 mg/mL (199.09 mM)
Ethanol 40 mg/mL (82.95 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG 400+5% Tween 80+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 482.19
化学式

C16H14F3IN2O4

CAS号 391210-10-9
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02510001 Recruiting Solid Tumor|Colorectal Cancer University of Oxford|Queen''s University Belfast|Oxford University Hospitals NHS Trust|Velindre NHS Trust|University Hospital Antwerp|Hospital Vall d''Hebron|Saint Antoine University Hospital|European Georges Pompidou Hospital|Pfizer|University of Turin Italy|Belfast Health and Social Care Trust|Beaumont Hospital|European Commission|Array BioPharma|University of Paris 5 - Rene Descartes November 2014 Phase 1
NCT02096471 Active not recruiting Neurofibromatosis Type 1 and Growing or Symptomatic Inoperable PN University of Alabama at Birmingham June 2014 Phase 2
NCT02022982 Active not recruiting KRAS Mutant Non-Small Cell Lung Cancer|Solid Tumors Dana-Farber Cancer Institute January 2014 Phase 1|Phase 2
NCT02039336 Recruiting Colorectal Cancer The Netherlands Cancer Institute|Pfizer January 2014 Phase 1|Phase 2
NCT02297802 No longer available Prior Treatment With PD-0325901 With Ongoing Clinical Response Sharp HealthCare June 2013 --
NCT01347866 Terminated Advanced Cancer Pfizer October 2011 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Whether the inhibitor PD0325901 interacts with other targets other than MEK?

  • 回答:

    PD0325901 has very high selectivity to MEK. In addition, it can also inhibits VEGF activity according to the reference: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713590/

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

相关MEK产品

Tags: 购买PD0325901 | PD0325901供应商 | 采购PD0325901 | PD0325901价格 | PD0325901生产 | 订购PD0325901 | PD0325901代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID